Squarepoint’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-12,233
| Closed | -$55.2K | – | 5101 |
|
|
2025
Q2 | $55.2K | Sell |
12,233
-116,294
| -90% | -$523K | ﹤0.01% | 4290 |
|
|
2025
Q1 | $569K | Buy |
128,527
+25,559
| +25% | +$148K | ﹤0.01% | 3171 |
|
|
2024
Q4 | $806K | Sell |
102,968
-51,963
| -34% | -$633K | ﹤0.01% | 3275 |
|
|
2024
Q3 | $2.04M | Buy |
154,931
+28,542
| +23% | +$362K | ﹤0.01% | 2055 |
|
|
2024
Q2 | $1.53M | Buy |
126,389
+74,452
| +143% | +$1.01M | ﹤0.01% | 2249 |
|
|
2024
Q1 | $844K | Buy |
+51,937
| New | +$700K | ﹤0.01% | 2708 |
|
|
2023
Q1 | – | Sell |
-91,143
| Closed | -$445K | – | 3893 |
|
|
2022
Q4 | $445K | Buy |
+91,143
| New | +$662K | ﹤0.01% | 2346 |
|
|
2021
Q3 | – | Sell |
-18,554
| Closed | -$627K | – | 3502 |
|
|
2021
Q2 | $627K | Sell |
18,554
-18,335
| -50% | -$589K | ﹤0.01% | 1975 |
|
|
2021
Q1 | $1.12M | Buy |
36,889
+17,174
| +87% | +$704K | 0.01% | 1420 |
|
|
2020
Q4 | $976K | Buy |
19,715
+4,180
| +27% | +$193K | 0.01% | 1353 |
|
|
2020
Q3 | $596K | Sell |
15,535
-696
| -4% | -$27.7K | 0.01% | 1300 |
|
|
2020
Q2 | $701K | Sell |
16,231
-21,719
| -57% | -$821K | 0.01% | 1130 |
|
|
2020
Q1 | $990K | Sell |
37,950
-34,538
| -48% | -$1M | 0.03% | 726 |
|
|
2019
Q4 | $2.27M | Buy |
72,488
+23,174
| +47% | +$686K | 0.01% | 840 |
|
|
2019
Q3 | $1.28M | Buy |
49,314
+29,614
| +150% | +$757K | 0.01% | 1062 |
|
|
2019
Q2 | $451K | Buy |
+19,700
| New | +$452K | ﹤0.01% | 1728 |
|
Other funds holding YMAB
Squarepoint's YMAB Position: Q3 2025 in Review
Squarepoint sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 12,233 shares — an estimated $55.2K sold.
Squarepoint first reported a position in YMAB in Q2 2019 and held it in 16 quarters. The position peaked at $2.27M in Q4 2019. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Squarepoint reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Squarepoint sold 12,233 Y-mAbs Therapeutics shares in Q3 2025, an estimated $55.2K.
- Squarepoint first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 16 quarters.
- Squarepoint's Y-mAbs Therapeutics position peaked at $2.27M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.